Erasca Extends Series B Financing to $236 Million

Aug 31, 2020•almost 5 years ago

Amount Raised

$236 Million

Round Type

series b

San Diego

Description

Erasca, a company whose mission is to erase cancer, today announced the completion of a $36 million extension of its Series B financing round, which brings the total round to $236 million. New investors include Partner Fund Management and OrbiMed.

Company Information

Company

Erasca

Location

San Diego, California, United States

About

At Erasca, our mission is embedded in our name: To erase cancer. Energized by recent scientific discoveries in drugging various biological drivers of cancer, we are advancing multiple programs that shut down key cancer pathways in order to solve oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. We also are pursuing additional pipeline expansion opportunities through academic and biopharmaceutical collaborations. Founded in 2018 and headquartered in San Diego, Erasca has raised $300 million in financing from investors who share the company’s bold mission, including ARCH Venture Partners, City Hill Ventures and Cormorant Asset Management. For more information, please visit www.erasca.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Erasca Extends Series B Financing to $236 Million

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information